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INTRODUCTION
Chronic transfusions are effective in preventing both initial and
recurrent strokes in patients with sickle cell disease (SCD) [1,2].
Accurate assessment of body iron is important in chronically
transfused patients. Individuals with high iron burden are at
significant risk for end organ damage and death due to cardiac
complications. For this reason patients receiving chronic transfu-
sions are placed on the iron chelator desferrioxamine. The dose or
frequency of administration of this drug needs to be adjusted.
Patientswith body iron burden in the normal rangemight experience
significant toxicity from deferoxamine while patients with high
levels of body iron may need to have the doses increased in order to
achievemore effective chelation [3]. Measurement of serum ferritin
levels is often used to assess body iron content [4–8]. In healthy
individuals, the concentration of serum ferritin is directly pro-
portional to the available storage iron in the body. These values vary
over a broad rangewhen compared to direct quantitation of liver iron
and are poor predictors of body iron stores [3–9]. In a series of 1184
liver biopsies in thalassemia patients, the correlation of serum
ferritin with liver iron was poor (r¼ 0.3) [10]. As a result of these
findings many experts recommend that body iron contents be
determined and followed directly by liver biopsies in these patients
[3]. Similar data are available in a limited number for patients with
sickle cell disease [11].
Transfusion therapy has been used to prevent stroke recurrence
in patients with SCD and now the results of the Stroke Prevention
Trial in Sickle Cell Disease (STOP) indicate that transfusions
are effective in preventing primary strokes in children at high risk.
A large number of children with sickle cell disease are being
chronically transfused and accurate guidelines for chelation are
needed in this patient population.We studied the correlation of LIC,
in liver biopsies, with serum ferritin in 39 patients with sickle cell
disease receiving chronic transfusion.
MATERIALS AND METHODS
Thirty-eight patients with homozygous sickle cell anemia
(HbSS) and one patient with sickle thalassemia (HbSb0) were
studied. Medical records of these patients were reviewed for the
following information: hemoglobin electrophoresis, transfusion
history, chelation therapy, ferritin levels, plasma vitamin C levels,
hepatitis B and C serology, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), alkaline phosphatase, bilirubin
direct and indirect, total protein and albumin. Serum ferritin
concentrations were determined by automated microparticle
enzyme immunoassay. Three ferritin measurements were used to
calculate a mean level for each patient. A serum ferritin level was
obtained at the time of the liver biopsy. The time interval between
liver biopsy and other serum ferritin levels ranged from 0 to
12 months (mean of 6 months).
Informed consent was obtained from each patient or parent prior
to each procedure. The liver tissues were collected during
percutaneous liver biopsy in thirty cases. Fourteen patients had
wedge liver biopsy; 11 during cholecystectomy, three during
splenectomy. Specimens were evaluated histologically by one
pathologist. Iron quantitation was performed in 40 of the 44 liver
biopsies, at Mayo Clinical Laboratories (Rochester, MN). All the
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work-up done on these patients was done as part of direct patient
care. The liver biopsies were performed to adjust iron chelation
therapy in these patients and not as part of the study. This
retrospective study was reviewed by the Institutional Review Board
at the Medical University of South Carolina and deemed exempted
from informed consent.
The association between serum ferritin levels (both themean and
the one closest in time to the liver biopsy) and iron quantitation was
measured using Spearman rank correlation coefficients, as both the
serum ferritin and iron quantitation were not normally distributed.
Since iron accumulates in tissues with age, the hepatic iron index
(hepatic iron concentration/age) corrects for this normal process.
Thus we also measured the correlation between serum ferritin and
the hepatic iron index. In addition, the correlations between the
iron measures and histological grade were calculated, and using
Wilcoxon rank sum tests, serum ferritin and liver iron were
compared between patientswith stage 1 fibrosis and thosewithmore
advanced fibrosis.
Sensitivity and specificity were determined for serum ferritin,
treating iron quantitation as the gold standard. Threshold values for
serum ferritin and liver iron were 2500 ng/ml and 7 mg/g,
respectively, as values above these cutoffs are traditionally treated
as markers of increased risk of cardiac disease and early death [9].
RESULTS
There were 25 males and 14 females, ages 6–23 years, with a
mean age of 12.7 years. None of the patients were positive for
hepatitis C or had other evidence of viral hepatitis on serology. All
patients had normal vitamin C levels. Patients had a mean ALT of
42.7 21.2 IU/l at the time of biopsy. Two patients had elevated
ALT and the value was within two times the upper limit of normal.
One patient had a liver biopsy because of abnormal liver enzymes
and hepatomegaly on physical exam.One patient had a concomitant
diagnosis of rheumatoid arthritis. All patients had a liver biopsy to
evaluate iron content and decide on initiation or adequacy of
chelation therapy. Five patients had a second liver biopsy as a
follow-up 29.8 9.2 months after the first biopsy (range 19–38).
One patient had received erratic transfusions and the liver biopsy
was done to evaluate the need for chelation therapy.
Patients were on chronic transfusion for a mean of 41.27
40.7 months (range 9–188). Thirty-eight were transfused for the
prevention of recurrent strokes. Patients transfused to prevent stroke
recurrence were kept at HbS< 30%, the others were kept at
HbS< 50%. Thirty-seven patients were on chelation therapy for
38.9 27.3 months (range 6–106). Thirty-two patients were on
chelation with subcutaneous (SC) deferoxamine (30–42 mg/kg
daily, 5 days per week). Three patients whowere noncompliant with
SC administration were admitted to the hospital once per week or
every 2 weeks to receive intravenous (IV) desferrioxamine. One
patient was on partial exchange transfusion because of poor
compliance with deferoxamine. Chronic transfusion was stopped
in one patient because of refusal of desferrioxamine; he was then
placed on hydroxyurea.Quantitative ironwasmoderately correlated
with the months of transfusion (r¼ 0.41, P¼ 0.011). Liver iron
content ranged from 1.8 to 67.97 mg/g dry weight with a mean of
15.27 mg/gm dry weight.
Serum ferritin ranged from 515 to 6076 ng/ml with a mean of
2808 1429 ng/ml. A moderate correlation (see Fig. 1) was
observed between the amount of iron on liver biopsy and both
the mean serum ferritin values (r¼ 0.46, P¼ 0.004) and the
serum value closest in time to the biopsy (r¼ 0.41, P¼ 0.009).
Mean serum ferritin was also moderately correlated with the
duration of transfusion (r¼ 0.40, P¼ 0.013), as was the correlation
between serum ferritin levels and hepatic iron index (r¼ 0.39,
P¼ 0.014).
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Fig. 1. Association between serum ferritin and liver iron. Mean refers to the mean of three samples of serum ferritin obtained in the 6–12 months
before the biopsy and closest to the value obtained closest to the time of biopsy. [Color figure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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Levels of more than or equal to 7 mg/g of liver iron and 2500 ng/
ml of serum ferritin were described as threshold values for a high
iron (i.e., being at risk for cardiac disease and early death). Using
these values, the sensitivity and specificity of the serum ferritin level
were determined to be 62.5% and 77.8%, respectively.
Sixty six percent (29/44) of liver biopsies led to changes
in chelation therapy. Four patients would not have been started on
chelation based on serum ferritin levels but were started based on
liver iron concentration. Eleven patients had an increase in the
subcutaneous dose of deferoxamine. Partial exchange transfusion
was started in seven patients because of evidence of significant iron
overload. Another seven patients were either started on IV desferal
or had changes made to it. In one patient after having an
improvement of iron content on the follow-up liver biopsy, the IV
deferoxamine dose was decreased.
All patients had hemosiderosis on liver biopsy. 10/44 (22.7%)
liver biopsies had grade 4 and 17/44 (38.6%) had grade 3 iron
staining.All patients had some degree offibrosis;most of themhad a
grade 1 (66%). Liver iron content did not differ significantly
(P¼ 0.99) between those with grade 1 fibrosis (mean SD:
15.3 13.4) and those with a higher grade (mean SD:
14.3 10.6). However, there was a strong correlation between liver
iron and histological grading of hemosiderosis or fibrosis (r¼ 0.78,
P< 0.0001). Three patients had portal fibrosis, despite being on
transfusion for less than 2 years and having a serum ferritin
<2000 ng/ml. Two of them were not receiving chelation. Liver
biopsy demonstrated evidence of chronic hepatitis in one patient
with normal liver enzymes. Another was found to have granuloma-
tous hepatitis and coagulative necrosis. This patient had positive
sputum cultures for M. tuberculosis. Iron staining did not correlate
with Kupffer cell hyperplasia in histological specimens.
DISCUSSION
Patients with thalassemiamajor who are transfused from infancy
develop iron overload. The target organs for damage as well as the
level at which tissue iron needs to be maintained to prevent cardiac
dysfunction and death have been well defined in this population.
Similar data are not available for patients with sickle cell disease an
increasing number of who are receiving chronic transfusions,
mostly for primary and secondary stroke prevention. The tissue iron
load in these patients has traditionally been evaluated by serum
ferritin measurements. In heavily transfused patients with thalasse-
mia and SCD, studies have demonstrated that serum ferritin values
are a poor and misleading measure of tissue iron load [4,11–13]. In
this study, we demonstrate that ferritin measurements could be
inaccurate in determining tissue iron content in individual patients
with sickle cell disease. Another finding was that in our patients the
incidence of end organ dysfunction, particularly cardiac, was low
despite LICs that have been associated with organ dysfunction in
thalassemia. The reasons for this are not clear and further studies are
needed to define tissue iron levels at which end organ dysfunction
will develop in patients with SCD.
There are several possible explanations for the poor correlation
between serum ferritin and LIC. Hemolysis and ineffective
erythropoiesis may play a role in the variability of ferritin levels
in these patients [4,11]. Furthermore, ferritin is an acute phase
reactant and may be increased by fever, acute infection, chronic
inflammation and liver disease. We attempted to eliminate the role
of acute changes by averaging ferritin values over one year but still
did not find a correlation with liver biopsy results. Ascorbate
deficiency, another cause for variation in ferritin levels, was not
common in our patients who had ascorbate levels measured
frequently. Regardless of the cause, serum ferritin was a very poor
predictor of body iron stores in patients with sickle cell disease and
significant changes were made in the management of 66% our
patients after liver biopsy and LIC results were obtained. These
changes included, starting chelation in patients whose ferritin levels
were low, and increasing the dose and/or intensity of chelation. This
was important in patients with very high iron levels, associated with
imminent organ dysfunction that required intravenous chelation.
Iron is unevenly distributed in the livers of b-thalassemia
patients, and the iron content determined in a small liver fragment
should be interpreted in caution [14]. Nonetheless, the use of needle
biopsies in evaluating liver iron content has been validated [15]. In
addition, liver biopsies provide a more accurate assessment of the
extent of the liver injury, inflammation, fibrosis, and cirrhosis. In our
patients the liver iron content did not correlate with fibrosis. Despite
having a significant level of iron overload, most of our patients had a
lowdegree offibrosis. These findings suggest that patients with SCD
have a different response to iron overload when compared to
patients with thalassemia or hemochromatosis. Another possible
explanation, however, could be that it is just a matter of time and
patients with sickle cell disease eventually develop significant
fibrosis and cirrhosis as a result of iron overload.
As increasing numbers of sickle cell patients are started on
chronic transfusion regimens, a reliable method for evaluating body
iron stores and monitoring chelation therapy is needed. Despite the
obvious limitations multiple serial ferritin measurements offer a
quick, inexpensive and non invasive method to follow patients with
iron overload on chelation. Percutaneous liver biopsy is a common
and safe procedure that is often performed at the bedside or in
the outpatient department [16–26]. In our patients, percutaneous
liver biopsy was not associated with complications and in a series of
1184 percutaneous liver biopsies in 501 thalassemic patients, the
complication rate was 0.5% and no complication was fatal [10].
Nonetheless, liver biopsy remains an invasive procedure and may
not be acceptable to many patients and practitioners. The
availability of new magnetic resonance based techniques may
replace liver biopsies for determination of liver iron content [27].
The newMRI techniques allow the non invasive quantitation of both
liver and cardiac iron. These technologies have been validated in
comparison to liver iron content from biopsies and are available at
many centers.
In light of recent advances, patients with SCD at risk for iron
overload should be followed with serial serum ferritin as well as
cardiac and liver iron quantitation by MRI (T2,T2* and R2).
Biopsies would then be reserved for a limited number of patients
who have persistent liver dysfunction, to evaluate fibrosis and other
histologic changes [27]. These MRI studies will allow for better
patient management and perhaps clarify the difference in cardiac
and liver iron accumulation in this patient population. Such data
may also point to different approaches to chelation as new oral
chelators are now available that may be more effective in removing
cardiac iron than desferrioxamine [28].
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